Curevac (CVAC)

$2.65

-0.26

(-8.93%)▲

Market is closed - opens 7 PM, 16 Apr 2024

Insights on Curevac

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 7.57M → 16.48M (in $), with an average increase of 54.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -128.78M → -48.68M (in $), with an average increase of 64.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 110.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.0% return, outperforming this stock by 342.3%

Performance

  • $2.61
    $2.91
    $2.65
    downward going graph

    1.51%

    Downside

    Day's Volatility :10.31%

    Upside

    8.93%

    downward going graph
  • $2.65
    $12.36
    $2.65
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :78.56%

    Upside

    78.56%

    downward going graph

Returns

PeriodCurevacSector (Health Care)Index (Russel 2000)
3 Months
-21.14%
-0.6%
0.0%
6 Months
-49.74%
5.9%
0.0%
1 Year
-63.35%
3.2%
-0.7%
3 Years
-97.34%
14.3%
-21.8%

Highlights

Market Capitalization
651.6M
Book Value
$2.69
Earnings Per Share (EPS)
-1.58
Wall Street Target Price
13.22
Profit Margin
0.0%
Operating Margin TTM
-332.92%
Return On Assets TTM
-18.03%
Return On Equity TTM
-49.26%
Revenue TTM
42.9M
Revenue Per Share TTM
0.2
Quarterly Revenue Growth YOY
47.0%
Gross Profit TTM
-91.5M
EBITDA
-242.1M
Diluted Eps TTM
-1.58
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.02
EPS Estimate Next Year
-0.97
EPS Estimate Current Quarter
-0.28
EPS Estimate Next Quarter
-0.23

Analyst Recommendation

Buy
    68%Buy
    25%Hold
    6%Sell
Based on 16 Wall street analysts offering stock ratings for Curevac(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
4
4
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 398.87%

Current $2.65
Target $13.22

Company Financials

FY18Y/Y Change
Revenue
14.7M
-
Net Income
-81.5M
-
Net Profit Margin
-553.5%
-
FY19Y/Y Change
Revenue
19.5M
↑ 35.31%
Net Income
-111.9M
↑ 40.19%
Net Profit Margin
-573.46%
↓ 19.96%
FY20Y/Y Change
Revenue
60.1M
↑ 180.78%
Net Income
-158.8M
↑ 29.24%
Net Profit Margin
-263.96%
↑ 309.5%
FY21Y/Y Change
Revenue
116.6M
↑ 110.61%
Net Income
-466.3M
↑ 218.98%
Net Profit Margin
-399.76%
↓ 135.8%
FY22Y/Y Change
Revenue
72.2M
↓ 34.54%
Net Income
-266.8M
↓ 39.51%
Net Profit Margin
-369.37%
↑ 30.39%
FY23Y/Y Change
Revenue
42.9M
↓ 36.4%
Net Income
-302.3M
↑ 21.39%
Net Profit Margin
-704.99%
↓ 335.62%
Q2 FY22Q/Q Change
Revenue
21.0M
↓ 51.13%
Net Income
-60.2M
↑ 2874.38%
Net Profit Margin
-285.83%
↓ 281.13%
Q3 FY22Q/Q Change
Revenue
11.0M
↓ 44.35%
Net Income
-46.8M
↓ 17.39%
Net Profit Margin
-424.26%
↓ 138.43%
Q4 FY22Q/Q Change
Revenue
12.5M
↑ 4.25%
Net Income
-138.0M
↑ 170.74%
Net Profit Margin
-1.1K%
↓ 677.49%
Q1 FY23Q/Q Change
Revenue
12.7M
↑ 0.0%
Net Income
-140.4M
↑ 0.0%
Net Profit Margin
-1.1K%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
8.3M
↓ 35.16%
Net Income
-73.6M
↓ 47.65%
Net Profit Margin
-889.48%
↑ 212.27%
Q3 FY23Q/Q Change
Revenue
16.5M
↑ 117.48%
Net Income
-48.7M
↓ 27.79%
Net Profit Margin
-295.34%
↑ 594.14%
FY18Y/Y Change
Total Assets
143.8M
-
Total Liabilities
107.1M
-
FY19Y/Y Change
Total Assets
146.3M
↑ 3.95%
Total Liabilities
194.3M
↑ 85.33%
FY20Y/Y Change
Total Assets
1.9B
↑ 1057.06%
Total Liabilities
984.0M
↑ 361.31%
FY21Y/Y Change
Total Assets
1.3B
↓ 23.36%
Total Liabilities
532.0M
↓ 41.28%
FY22Y/Y Change
Total Assets
921.8M
↓ 25.71%
Total Liabilities
350.5M
↓ 30.34%
Q2 FY22Q/Q Change
Total Assets
967.2M
↓ 20.07%
Total Liabilities
316.1M
↓ 35.58%
Q3 FY22Q/Q Change
Total Assets
895.0M
↓ 1.65%
Total Liabilities
280.7M
↓ 5.65%
Q4 FY22Q/Q Change
Total Assets
921.8M
↓ 5.5%
Total Liabilities
350.5M
↑ 14.6%
Q1 FY23Q/Q Change
Total Assets
938.4M
↑ 0.0%
Total Liabilities
356.8M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
981.4M
↑ 4.53%
Total Liabilities
273.2M
↓ 23.47%
Q3 FY23Q/Q Change
Total Assets
842.6M
↓ 6.33%
Total Liabilities
240.3M
↓ 4.05%
FY18Y/Y Change
Operating Cash Flow
-84.8M
-
Investing Cash Flow
-4.9M
-
Financing Cash Flow
-128.1K
-
FY19Y/Y Change
Operating Cash Flow
-97.4M
↑ 17.34%
Investing Cash Flow
31.6M
↓ 760.91%
Financing Cash Flow
76.1M
↓ 60795.54%
FY20Y/Y Change
Operating Cash Flow
642.6M
↓ 700.72%
Investing Cash Flow
-55.7M
↓ 260.65%
Financing Cash Flow
1.0B
↑ 1106.01%
FY21Y/Y Change
Operating Cash Flow
-830.3M
↓ 240.34%
Investing Cash Flow
-144.8M
↑ 182.5%
Financing Cash Flow
390.7M
↓ 57.92%
Q2 FY22Q/Q Change
Operating Cash Flow
-67.6M
↓ 64.68%
Investing Cash Flow
-28.8M
↑ 60.2%
Financing Cash Flow
4.0M
↓ 111.54%
Q3 FY22Q/Q Change
Operating Cash Flow
-35.3M
↓ 44.46%
Investing Cash Flow
-27.4M
↑ 1.14%
Financing Cash Flow
26.0M
↑ 584.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-52.6M
↑ 36.67%
Investing Cash Flow
-14.4M
↓ 51.8%
Financing Cash Flow
35.7M
↑ 25.83%
Q1 FY23Q/Q Change
Operating Cash Flow
-53.5M
↑ 0.0%
Investing Cash Flow
-14.6M
↑ 0.0%
Financing Cash Flow
36.3M
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-70.0M
↑ 30.62%
Investing Cash Flow
-14.6M
↑ 0.0%
Financing Cash Flow
-1.3M
↓ 103.59%
Q3 FY23Q/Q Change
Operating Cash Flow
-60.6M
↓ 5.52%
Investing Cash Flow
-13.4M
↑ 0.0%
Financing Cash Flow
-1.2M
↑ 1.25%

Technicals Summary

Sell

Neutral

Buy

Curevac is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Curevac
Curevac
-11.82%
-49.74%
-63.35%
-97.34%
-94.79%
Moderna, Inc.
Moderna, Inc.
1.24%
14.36%
-26.97%
-34.23%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.2%
7.24%
10.36%
82.9%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-5.94%
23.09%
45.57%
248.23%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.6%
6.03%
21.0%
79.35%
120.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Curevac
Curevac
NA
NA
NA
-1.02
-0.49
-0.18
NA
2.69
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.75
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.03
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.46
46.46
2.4
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.57
28.57
0.53
16.62
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Curevac
Curevac
Buy
$651.6M
-94.79%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.3B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.3B
140.93%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$564.6B
394.48%
46.46
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.5B
120.62%
28.57
36.68%

Institutional Holdings

  • Citadel Advisors Llc

    1.37%

  • RA Capital Management, LLC

    1.23%

  • Millennium Management LLC

    1.22%

  • T. Rowe Price Associates, Inc.

    1.04%

  • BlackRock Inc

    0.81%

  • Camber Capital Management LLC

    0.78%

Corporate Announcements

  • Curevac Earnings

    Curevac’s price-to-earnings ratio stands at None

    Read More

Company Information

founded in 2000 as a spin-off from the university of tϋbingen in germany, curevac is a leading company in the field of mrna technology and was the first company to start clin-ical trials on mrna-based drugs. the biopharmaceutical company has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes. the basic principle of curevac's proprietary technology is the use of mrna as a data car-rier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. the company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies. since its inception, strongly backed by sap founder dietmar hopp’s dievini, curevac has received approximately $420 million (€400 million) in equity investments including an investment of the bill & melinda gates foundation of $ 52million in 2015. curevac has entered into various collaborations with multinational corporations and o

Organization
Curevac
Employees
904
CEO
Mr. Pierre Kemula B.Sc.
Industry
Health Technology

Discover More

FAQs